RESTON, Virginia — Alan Packard, PhD, has been elected 2020-21 president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Packard is associate professor of radiology at Harvard Medical School, director of radiopharmaceutical research and a senior research associate in nuclear medicine at Boston Children's Hospital in Boston, Massachusetts. The new slate of officers was introduced during the Society of Nuclear Medicine and Molecular Imaging’s 2020 Virtual Annual Meeting on July 11-14.
“SNMMI’s strength comes from its breadth of membership, with physicians, scientists and technologists working together to advance nuclear medicine and molecular imaging in order to provide patients with the best possible care,” Packard noted. “This is a very exciting time for the field of nuclear medicine, and as president of SNMMI, I look forward to working with my fellow members to build upon recent breakthroughs in the field, especially in the area of theranostics, and to demonstrating the value of nuclear medicine to those outside our field.”
His overall goal for the coming year is to enhance the value of SNMMI membership. He will accomplish this by working to enhance the society’s core member benefits—the SNMMI Annual Meeting, continuing education, and The Journal of Nuclear Medicine—and by strengthening the society and nuclear medicine more broadly through the SNMMI Value Initiative, SNMMI’s strategic vision for working with industry and other partners to demonstrate the crucial role of nuclear medicine and molecular imaging to the medical community, regulators, patients and the public.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Packard’s laboratory at Boston Children’s Hospital is engaged in the development of radiolabeled proteins for multiple applications, including cancer imaging and therapy, and 18F-labeled small molecules for myocardial perfusion imaging. The focus of the cancer program is on developing copper-64 (64Cu)- and zirconium-89 (89Zr)-labeled antibodies that can be used to noninvasively evaluate disease status, as well as on developing antibodies labeled with therapeutic radionuclides, such as lutetium-177 (177Lu) and copper-67 (67Cu), that can be used to treat cancer.
A prolific researcher, author and editor, Packard has coauthored more than 70 articles and has written book chapters on topics ranging from pediatric nuclear medicine and new procedures in nuclear medicine to application of nanoparticles in medical imaging. He is a regular lecturer and invited speaker at conferences across the United States and around the world. He is a reviewer for a variety of journals, including The Journal of Nuclear Medicine, Nuclear Medicine and Biology, Inorganic Chemistry, The Journal of Inorganic Biochemistry, Cancer Research, Molecular Imaging, Bioconjugate Chemistry, Cancer Biotherapy & Radiopharmaceuticals, The Journal of Medicinal Chemistry, Applied Radiation and Isotopes, and the Journal of the American Chemical Society. He is currently on the advisory board for Molecular and Cellular Therapies.